CCND3 is altered in 1.04% of malignant solid tumor patients with CCND3 Amplification present in 0.65% of all malignant solid tumor patients [4].

CCND3 Amplification is an inclusion criterion in 7 clinical trials for malignant solid tumor, of which 6 are open and 1 is closed. Of the trials that contain CCND3 Amplification and malignant solid tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 6 are phase 2 (5 open) [5].

CCND3 is altered in 0.87% of breast carcinoma patients with CCND3 Amplification present in 0.6% of all breast carcinoma patients [4].

CCND3 Amplification is an inclusion criterion in 2 clinical trials for breast carcinoma, of which 0 are open and 2 are closed. Of the trials that contain CCND3 Amplification and breast carcinoma as inclusion criteria, 2 are phase 2 (0 open) [5].

CCND3 is altered in 5.59% of non-hodgkin lymphoma patients with CCND3 Amplification present in 0.2% of all non-hodgkin lymphoma patients [4].

CCND3 Amplification is an inclusion criterion in 2 clinical trials for non-hodgkin lymphoma, of which 2 are open and 0 are closed. Of the trials that contain CCND3 Amplification and non-hodgkin lymphoma as inclusion criteria, 2 are phase 2 (2 open) [5].

CCND3 is altered in 12.45% of osteosarcoma patients with CCND3 Amplification present in 12.66% of all osteosarcoma patients [4].

CCND3 Amplification is an inclusion criterion in 1 clinical trial for osteosarcoma, of which 1 is open and 0 are closed. Of the trial that contains CCND3 Amplification and osteosarcoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CCND3 is altered in 6.25% of dedifferentiated chondrosarcoma patients with CCND3 Amplification present in 6.25% of all dedifferentiated chondrosarcoma patients [4].

CCND3 Amplification is an inclusion criterion in 1 clinical trial for dedifferentiated chondrosarcoma, of which 1 is open and 0 are closed. Of the trial that contains CCND3 Amplification and dedifferentiated chondrosarcoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CCND3 is altered in 3.32% of esophageal carcinoma patients with CCND3 Amplification present in 2.84% of all esophageal carcinoma patients [4].

CCND3 Amplification is an inclusion criterion in 1 clinical trial for esophageal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CCND3 Amplification and esophageal carcinoma as inclusion criteria, 1 is phase 2 (0 open) [5].

CCND3 is altered in 2.15% of gastric carcinoma patients with CCND3 Amplification present in 1.6% of all gastric carcinoma patients [4].

CCND3 Amplification is an inclusion criterion in 1 clinical trial for gastric carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CCND3 Amplification and gastric carcinoma as inclusion criteria, 1 is phase 2 (0 open) [5].

CCND3 is altered in 0.88% of chondrosarcoma patients with CCND3 Amplification present in 0.91% of all chondrosarcoma patients [4].

CCND3 Amplification is an inclusion criterion in 1 clinical trial for chondrosarcoma, of which 1 is open and 0 are closed. Of the trial that contains CCND3 Amplification and chondrosarcoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CCND3 is altered in 1.13% of cancer patients with CCND3 Amplification present in 0.61% of all cancer patients [4].

CCND3 Amplification is an inclusion criterion in 1 clinical trial for cancer, of which 0 are open and 1 is closed. Of the trial that contains CCND3 Amplification and cancer as inclusion criteria, 1 is phase 2 (0 open) [5].

CCND3 is altered in 1.12% of colorectal carcinoma patients with CCND3 Amplification present in 0.55% of all colorectal carcinoma patients [4].

CCND3 Amplification is an inclusion criterion in 1 clinical trial for colorectal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CCND3 Amplification and colorectal carcinoma as inclusion criteria, 1 is phase 2 (0 open) [5].

CCND3 is altered in 0.66% of soft tissue sarcoma patients with CCND3 Amplification present in 0.38% of all soft tissue sarcoma patients [4].

CCND3 Amplification is an inclusion criterion in 1 clinical trial for soft tissue sarcoma, of which 1 is open and 0 are closed. Of the trial that contains CCND3 Amplification and soft tissue sarcoma as inclusion criteria, 1 is phase 2 (1 open) [5].

CCND3 is altered in 0.27% of germ cell tumor patients with CCND3 Amplification present in 0.14% of all germ cell tumor patients [4].

CCND3 Amplification is an inclusion criterion in 1 clinical trial for germ cell tumor, of which 0 are open and 1 is closed. Of the trial that contains CCND3 Amplification and germ cell tumor as inclusion criteria, 1 is phase 2 (0 open) [5].

CCND3 is altered in 0.61% of squamous cell lung carcinoma patients with CCND3 Amplification present in 0.11% of all squamous cell lung carcinoma patients [4].

CCND3 Amplification is an inclusion criterion in 1 clinical trial for squamous cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CCND3 Amplification and squamous cell lung carcinoma as inclusion criteria, 1 is no phase specified (1 open) [5].

CCND3 is altered in 0.39% of histiocytic and dendritic cell neoplasm patients [4].

CCND3 Amplification is an inclusion criterion in 1 clinical trial for histiocytic and dendritic cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains CCND3 Amplification and histiocytic and dendritic cell neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].